|
市場調査レポート
商品コード
1373714
コンパニオンアニマル診断サービスの世界市場規模、シェア、産業動向分析レポート:タイプ別、動物種別、検査カテゴリー別、地域別展望と予測、2023年-2030年Global Companion Animal Diagnostic Services Market Size, Share & Industry Trends Analysis Report By Type (Point-of-Care and Laboratory-based), By Animal Type, By Testing Category, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
コンパニオンアニマル診断サービスの世界市場規模、シェア、産業動向分析レポート:タイプ別、動物種別、検査カテゴリー別、地域別展望と予測、2023年-2030年 |
出版日: 2023年09月30日
発行: KBV Research
ページ情報: 英文 302 Pages
納期: 即納可能
![]() |
コンパニオンアニマル診断サービス市場規模は2030年までに104億米ドルに達し、予測期間中にCAGR 7.4%の市場成長率で上昇すると予測されます。
KBV Cardinalのマトリックスに掲載された分析によると、Thermo Fisher Scientific Inc.が同市場におけるトップランナーです。Zoetis, Inc.、Fujifilm Holdings Corporation、IDEXX Laboratories, Inc.などの企業が市場の主要なイノベーターです。2022年12月、富士フイルムホールディングスはInspirata, Inc.を買収し、病理画像とデータを医療機関の電子カルテシステムに統合しました。さらに、この買収は、腫瘍患者の指定治療を簡素化するのに役立っています。
市場成長要因
診断技術の進歩
デジタルX線撮影、超音波検査、遺伝子検査、PCRアッセイなどの診断技術の進歩により、ペットの診断サービスの精度と範囲が向上しています。デジタルX線技術は、従来のフィルムベースのX線撮影に大きく取って代わっています。より鮮明で迅速な撮影が可能になり、動物やスタッフの放射線被ばくが低減され、専門医と簡単に画像を共有して遠隔診察ができるようになりました。超音波技術も進歩し、軟部組織や臓器をより高解像度で詳細に撮影できるようになりました。CTスキャンやMRIスキャンは、非常に鮮明な3次元画像を提供し、神経疾患、腫瘍、筋骨格系の損傷などの複雑な状態の診断に役立ちます。このような診断技術の進歩により、コンパニオンアニマルのケアの質が向上し、動物病院が提供するサービスの幅が広がっています。技術の進化に伴い、診断能力はさらに高度化し、市場のさらなる向上に寄与するものと思われます。
ペットの健康に対する意識の高まり
ペットの飼い主は、動物の予防医療や病気の早期発見の重要性をますます認識するようになっています。この意識が、ペットの診断サービスを求める原動力となっています。定期検診や予防接種の重要性を知っている飼い主は、動物病院への定期的な受診を予定する傾向があります。このような受診には、健康診断の一環として診断テストが含まれることが多いです。知識のある飼い主は、病気の早期発見がより効果的な治療につながり、ペットにとってより良い結果をもたらすことを理解しています。そのような飼い主は、一般的な健康問題に対する診断テストやスクリーニングを要求する傾向があります。このようなアプローチには、治療計画の指針となる診断テストが含まれることが多いです。ペットの健康に対する意識の高まりは、市場に利益をもたらし、ペットの寿命と幸福を向上させる。このような意識が高まるにつれ、診断サービスに対する需要は引き続き堅調に推移し、市場の進歩をさらに促進するものと思われます。
市場抑制要因
診断サービスのコスト高
特定の診断検査や処置にかかる費用は、一部の飼い主、特に経済的に余裕のない飼い主にとっては高額です。そのため、必要な獣医療や診断を受けるのが遅れる可能性があります。診断費用が高額になると、飼い主は定期検診やスクリーニングなどの予防医療への投資を控えるようになります。その結果、病気の早期発見や早期介入の機会を逃すことになります。地方や動物医療サービスが十分でない地域では、診断費用がペットのヘルスケアにとって大きな障壁となります。ペットの飼い主は、安価なサービスを受けるために長距離を移動する必要があります。そのため、診断サービスのコストが高いことが、市場に大きな課題をもたらしています。
タイプ別展望
タイプ別では、サービス市場はポイントオブケア(POC)型とラボ型に分類されます。2022年には、ポイントオブケア(POC)分野が市場で最大の売上シェアを占めました。POC分野は遠隔医療プラットフォームと連携しており、獣医師がペットの飼い主と遠隔で相談しながら、POC診断を使って動物の健康状態を評価することができます。POC診断は、コンパニオンアニマルの潜在的な症例を迅速に特定することにより、人獣共通感染症のサーベイランスを支援し、公衆衛生の取り組みに貢献します。POC分野の成長は、コンパニオンアニマル・ヘルスケアにおける、便利で迅速な現場診断ソリューションに対する需要の増加によって牽引されています。
動物種の展望
動物の種類により、市場は犬、猫、馬、その他に分けられます。猫セグメントは2022年の市場で顕著な収益シェアを記録しました。猫は長生きするようになり、高齢猫の人口が増加しています。この年齢層では、腎臓病や関節炎のような加齢に関連した健康上の懸念を管理するため、より頻繁な診断評価が必要となります。腸内寄生虫や心臓病のような寄生虫の診断検査は、猫の健康にとって不可欠です。猫の個体数の増加に伴い、予防診断サービスの需要も増加しています。
検査カテゴリーの展望
検査カテゴリー別に見ると、市場は臨床化学、微生物学、寄生虫学、病理組織学、細胞病理学、血液学、免疫学・血清学、画像診断、分子診断、その他に分類されます。2022年には、臨床化学分野が市場で最も高い収益シェアを占めました。臨床化学検査はコンパニオンアニマルの全体的な健康と幸福を評価するために日常的に使用されます。臨床化学検査は、獣医師が動物の健康状態を長期にわたってモニターするためのベースラインデータを提供します。臨床化学検査はコンパニオンアニマルの様々な病気や健康状態の存在を検出することができます。
地域別展望
地域別では、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米が最も高い収益シェアを生み出し、市場をリードしました。北米は世界最大級の市場です。ペットの飼育数の増加、ペットの健康に対する意識の高まり、診断技術の進歩、ペットの予防ヘルスケア重視の高まりにより、市場は成長を続けています。北米各地の動物病院やクリニックでは、血液検査、尿検査、放射線検査、超音波検査、内視鏡検査など、さまざまな診断サービスを提供しています。これらの施設はコンパニオンアニマルに包括的なケアを提供しています。北米は、ペットの飼育動向、先進的なヘルスケア実践、ペットの健康と福祉への強い関心に後押しされ、堅調な成長市場を誇っています。この地域は、動物用診断薬の技術革新と導入の最前線に位置しています。
The Global Companion Animal Diagnostic Services Market size is expected to reach $10.4 billion by 2030, rising at a market growth of 7.4% CAGR during the forecast period.
Cytopathology is performed in real-time during procedures. This immediate feedback aids veterinarians in making on-the-spot decisions about patient care. Thus, the cytopathology segment garnered $342.6 million revenue in the market in 2022. Cytopathology provides rapid results, often within minutes to hours, allowing veterinarians to diagnose and initiate treatment for companion animals quickly. This is particularly valuable in emergency cases and when prompt decisions are essential.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, Mars, Inc. completed the acquisition of Heska Corporation. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions. Additionally, In September, 2022, Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc. is the forerunner in the Market. Companies such as Zoetis, Inc., Fujifilm Holdings Corporation, IDEXX Laboratories, Inc. are some of the key innovators in Market. In December, 2022, Fujifilm Holdings Corporation acquired Inspirata, Inc., to merge pathology images and data into the electronic health record system of the healthcare organizations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Market Growth Factors
Advancements in diagnostic technologies
Ongoing advancements in diagnostic technologies, such as digital radiography, ultrasound, genetic testing, and PCR assays, have improved the accuracy and range of pet diagnostic services. Digital X-ray technology has largely replaced traditional film-based radiography. It provides clearer and faster imaging, reduces radiation exposure for animals and staff, and allows for easy sharing of images with specialists for remote consultation. Ultrasound technology has advanced, offering higher resolution and better detail for imaging soft tissues and organs. CT and MRI scans provide three-dimensional images with exceptional clarity, aiding in diagnosing complex conditions such as neurological disorders, tumors, and musculoskeletal injuries. These advancements in diagnostic technologies have enhanced the quality of care for companion animals and expanded the range of services that veterinary clinics offer. As technology evolves, diagnostic capabilities will likely become even more advanced, contributing to further improvements in market.
Rising awareness of pet health
Pet owners are becoming increasingly conscious of the significance of preventive care and early disease detection in their animals. This awareness drives them to seek diagnostic services for their pets. Pet owners who know the importance of regular checkups and vaccinations are more likely to schedule routine visits to veterinary clinics. These visits often include diagnostic tests as part of the wellness examination. Knowledgeable pet owners understand that early detection of diseases can lead to more effective treatments and better outcomes for their pets. They are more likely to request diagnostic tests and screenings for common health issues. These approaches often involve diagnostic tests to guide treatment plans. The rising awareness of pet health benefits the market and improves pet longevity and well-being. As this awareness grows, the demand for diagnostic services will likely remain strong, further driving advancements in market.
Market Restraining Factors
High cost of diagnostic services
The cost of certain diagnostic tests and procedures is prohibitive for some pet owners, especially those with limited financial resources. This can lead to delays in seeking necessary veterinary care and diagnostics. High diagnostic costs discourage pet owners from investing in preventive care, including regular checkups and screenings. This can result in missed opportunities for early disease detection and intervention. In rural or underserved areas, where veterinary services are less abundant, the cost of diagnostics can be a significant barrier to pet healthcare. Pet owners need to travel long distances to access affordable services. Therefore, the high costs of diagnostic services pose a significant challenge to the market.
Type Outlook
Based on type, the services market is classified into point-of-care (POC) and laboratory-based. In 2022, the point-of-care (POC) segment witnessed the largest revenue share in the market. The POC segment aligns with telemedicine platforms, allowing veterinarians to consult remotely with pet owners while using POC diagnostics to assess an animal's health condition. POC diagnostics aid in surveilling zoonotic diseases by quickly identifying potential cases in companion animals, thus contributing to public health efforts. The growth of the POC segment is driven by the increasing demand for convenient, rapid, on-site diagnostic solutions in companion animal healthcare.
Animal Type Outlook
On the basis of animal type, the market is divided into dogs, cats, horses, and others. The cats segment recorded a remarkable revenue share in the market in 2022. Cats are living longer, and the senior cat population is growing. This age group requires more frequent diagnostic assessments to manage age-related health concerns like kidney disease and arthritis. Diagnostic tests for parasites like intestinal worms and heartworms are essential for the health of cats. As the cat population increases, so does the demand for preventive diagnostic services.
Testing Category Outlook
By testing category, the market is categorized into clinical chemistry, microbiology, parasitology, histopathology, cytopathology, hematology, immunology & serology, imaging, molecular diagnostics, and others. In 2022, the clinical chemistry segment held the highest revenue share in the market. Clinical chemistry tests are routinely used to assess companion animals' overall health and well-being. They provide baseline data veterinarians use to monitor an animal's health over time. Clinical chemistry tests can detect the presence of various diseases and health conditions in companion animals.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, North America led the market by generating the highest revenue share. North America has one of the largest markets globally. The market continues to grow due to increasing pet ownership, rising awareness of pet health, advancements in diagnostic technologies, and a growing emphasis on preventive healthcare for pets. Veterinary clinics and hospitals across North America offer various diagnostic services, including blood tests, urinalysis, radiology, ultrasonography, and endoscopy. These facilities provide comprehensive care for companion animals. North America boasts a robust and growing market, driven by pet ownership trends, advanced healthcare practices, and a strong emphasis on pet health and well-being. This region remains at the forefront of veterinary diagnostics innovation and adoption.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., IDEXX Laboratories, Inc., Mars Inc., Fujifilm Holdings Corporation, Embark Veterinary, Inc., Thermo Fisher Scientific Inc., Patterson Companies, Inc., Randox Laboratories Limited, CVS Group Plc, and Neogen Corporation
Recent Strategies Deployed in Companion Animal Diagnostic Services Market
Partnerships, Collaborations, and Agreements:
Apr-2023: Thermo Fisher Scientific Inc. partnered with ALPCO-GeneProof, a global leader in immunodiagnostics and molecular diagnostics. Through this partnership, the TaqPath Menu | GeneProof PCR kits were introduced into the market, which strengthened the supply chains and the support systems of Thermo Fisher.
Jan-2023: Thermo Fisher Scientific Inc. formed a partnership with AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company. Under this partnership, a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib) was launched which would ease the treatment of patients with non-small cell lung cancer (NSCLC).
Oct-2022: CVS Group plc came into a partnership with Provet Cloud, an easy-to-use cloud-based veterinary practice management software. With this Partnership, CVS Group bettered its operations through Provet Cloud's large-scale implementations and open software infrastructure.
Jul-2020: Thermo Fisher Scientific Inc. signed an agreement with Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan. With this agreement, the use of the Oncomine Dx Target Test was expanded in Japan.
Product Launches and Product Expansions:
Aug-2023: Neogen Corporation Launched Igenity Enhanced Dairy, a progressive genome data management tool. Igenity Enhanced Dairy is a digital service helping dairy producers to improve their mating decisions.
Jun-2023: Neogen Corporation introduced My CatScan 2.0, facilitating genetic screening in cats. My CatScan 2.0 provides simplified experience through the utilization of a simple cheek swab method and offers data in case of over 120 genetic health conditions.
May-2023: Neogen Corporation released two assays, Reveal for Histamine and Reveal Q+ for Histamine, which help in histamine detection. Reveal and Reveal Q+ assays use water extraction method to provide results quickly, prevent disposition of chemicals and reduce the testing time.
Sep-2022: Neogen Corporation unveiled Encompass platform, for accelerating genomic results management and visualization. The Encompass platform empowers Igenity users to regulate their data and increase the benefits of genome testing.
Acquisition and Mergers:
Jun-2023: Mars, Inc. completed the acquisition of Heska Corporation, engaged in developing medical devices to improve the quality of pet care. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions.
Dec-2022: Fujifilm Holdings Corporation acquired Inspirata, Inc., a leading provider of AI-NLP powered oncology informatics solutions. Through this acquisition, Fujifilm developed its Synapse Enterprise Imaging thus helping to merge pathology images and data into the electronic health record system of the healthcare organisations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Sep-2022: Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Sep-2022: Zoetis, Inc. took over NewMetrica, a developer of instruments to measure the quality of life in animals. Through this acquisition, Zoetis strengthened its capabilities and magnified expertise in quality-of-life assessments for the betterment of well-being of animals.
Jun-2022: Zoetis Inc. acquired Basepaws Inc., a petcare genetics company. Under the acquisition, Zoetis upgraded its portfolio in precision animal health and created its future roadmap towards innovations in petcare.
Jun-2021: IDEXX Laboratories, Inc. took over ezyVet, a cloud-based Practice Management software. Through this acquisition, IDEXX broadened its cloud software products that helped customers to raise the standard of care provided to the patients, improve efficiency and communications with the pet owners.
Sep-2021: Neogen Corporation took over CAPInnoVet, Inc., a fast-growing companion animal products company. Through this acquisition, Neogen paved its roadmap into the parasiticide market and improved its position within the Animal Safety business segment.
Jan-2021: Neogen Corporation acquired Megazyme, Ltd., a world leader in the development of biochemical assay kits. With this acquisition, Neogen bettered its relationship with the food producers and companies operating in the food security and quality business.
Market Segments covered in the Report:
By Type
By Animal Type
By Testing Category
By Geography
Companies Profiled
Unique Offerings from KBV Research